Transformative $2.4 Billion Acquisition: AstraZeneca Revolutionizes Cancer Treatment with Fusion Pharmaceuticals

AstraZeneca has acquired Fusion Pharmaceuticals for approximately $2.4 billion to enhance its oncology portfolio with Fusion's radioconjugates, including the advanced FPI-2265 program, and strengthen its presence in Canada.




